Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Analysis of baseline parameters in the HALT polycystic kidney disease trials.

Torres VE, Chapman AB, Perrone RD, Bae KT, Abebe KZ, Bost JE, Miskulin DC, Steinman TI, Braun WE, Winklhofer FT, Hogan MC, Oskoui FR, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin DR, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Meyers CM, Schrier RW; HALT PKD Study Group..

Kidney Int. 2012 Mar;81(6):577-85. doi: 10.1038/ki.2011.411.

PMID:
22205355
2.

Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies.

Chapman AB.

Clin J Am Soc Nephrol. 2008 Jul;3(4):1197-204. doi: 10.2215/CJN.00060108. Review.

PMID:
18579674
3.

Renin-Angiotensin-aldosterone system in autosomal dominant polycystic kidney disease.

Tkachenko O, Helal I, Shchekochikhin D, Schrier RW.

Curr Hypertens Rev. 2013 Feb;9(1):12-20. Review.

PMID:
23971639
4.

Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?

Weir MR.

Clin Ther. 2007 Sep;29(9):1803-24. Review.

PMID:
18035185
5.

Effect of blood pressure lowering on markers of kidney disease progression.

Udani SM, Koyner JL.

Curr Hypertens Rep. 2009 Oct;11(5):368-74. Review.

PMID:
19737454
6.

An update on proteinuric chronic kidney disease: the dual-goal approach.

Hirsch S.

Cleve Clin J Med. 2008 Oct;75(10):705-13. Review.

PMID:
18939386
8.

Renal protection in hypertensive patients: selection of antihypertensive therapy.

Wenzel RR.

Drugs. 2005;65 Suppl 2:29-39. Review.

PMID:
16398060
9.

Autosomal dominant polycystic kidney disease: new insights into treatment.

Helal I.

Saudi J Kidney Dis Transpl. 2013 Mar;24(2):230-4. Review.

PMID:
23538343
10.

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.

Sharma P, Blackburn RC, Parke CL, McCullough K, Marks A, Black C.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007751. doi: 10.1002/14651858.CD007751.pub2. Review.

PMID:
21975774
11.

Lessons from the African-American Study of Kidney Disease and Hypertension: an update.

Toto RD.

Curr Hypertens Rep. 2006 Oct;8(5):409-12. Review.

PMID:
16965728
12.

Treatment of hypertension in chronic kidney disease.

Toto RD.

Semin Nephrol. 2005 Nov;25(6):435-9. Review.

PMID:
16298269
13.

Pharmacological management of polycystic kidney disease.

Wüthrich RP, Mei C.

Expert Opin Pharmacother. 2014 Jun;15(8):1085-95. doi: 10.1517/14656566.2014.903923. Review.

PMID:
24673552
14.

Polycystic kidney disease: new horizons and therapeutic frontiers.

Czarnecki PG, Steinman TI.

Minerva Urol Nefrol. 2013 Mar;65(1):61-8. Review.

PMID:
23538311
15.

Why kidneys fail in autosomal dominant polycystic kidney disease.

Grantham JJ, Mulamalla S, Swenson-Fields KI.

Nat Rev Nephrol. 2011 Aug 23;7(10):556-66. doi: 10.1038/nrneph.2011.109. Review.

PMID:
21862990
16.

The Treatment of Autosomal Dominant Polycystic Kidney Disease.

Kühn WE, Walz G.

Dtsch Arztebl Int. 2015 Dec 21;112(51-52):884-90. doi: 10.3238/arztebl.2015.0884. Review.

PMID:
26900155
17.

Treatment strategies and clinical trial design in ADPKD.

Torres VE.

Adv Chronic Kidney Dis. 2010 Mar;17(2):190-204. doi: 10.1053/j.ackd.2010.01.006. Review.

PMID:
20219622
18.

Polycystic liver diseases: advanced insights into the molecular mechanisms.

Perugorria MJ, Masyuk TV, Marin JJ, Marzioni M, Bujanda L, LaRusso NF, Banales JM.

Nat Rev Gastroenterol Hepatol. 2014 Dec;11(12):750-61. doi: 10.1038/nrgastro.2014.155. Review.

PMID:
25266109
Items per page

Supplemental Content

Support Center